Selexis is a CMO for the production of recombinant proteins using mammalian cells. JSR, which operates a Life Science Business directed towards in-vitro diagnostics and reagents, bioprocess materials, materials for personalized medicine and development of biotechnology-based medicine, had already acquired KBI Biopharma, a US-based CDMO, in 2015.

JSR news release, June 14, 2017